Media coverage about Grifols SA, Barcelona (NASDAQ:GRFS) has been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Grifols SA, Barcelona earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.2213537407612 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- ETFs with exposure to Grifols SA : December 5, 2017 (finance.yahoo.com)
- First Week of GRFS January 2018 Options Trading (stockoptionschannel.com)
- Head-To-Head Analysis: Sevion Therapeutics (SVON) and Grifols (GRFS) (americanbankingnews.com)
- Head-To-Head Comparison: Grifols (GRFS) and Jazz Pharmaceuticals (JAZZ) (americanbankingnews.com)
Several research firms have weighed in on GRFS. Zacks Investment Research lowered Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. UBS downgraded Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research note on Friday, November 24th. Finally, Citigroup began coverage on Grifols SA, Barcelona in a research note on Tuesday, October 31st. They issued a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $24.00.
WARNING: “Grifols SA, Barcelona (GRFS) Earning Somewhat Positive Media Coverage, Accern Reports” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/12/05/grifols-sa-barcelona-grfs-earning-somewhat-positive-media-coverage-accern-reports.html.
Grifols SA, Barcelona Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.